ETFMG U.S. Alternative Harvest ETF (MJUS) Stock Analysis
DELISTED 2025
What happened to ETFMG U.S. Alternative Harvest ETF (MJUS) stock?
ETFMG U.S. Alternative Harvest ETF (MJUS) no longer trades on public markets. It was delisted in January 2025. The figures below are historical and are not a current quote.
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
ETFMG U.S. Alternative Harvest ETF (MJUS) trades at $0.7595. ETFMG U. S. Alternative Harvest ETF (MJUS) focuses on investing in companies that derive significant revenue from the cannabis business in the United States. Market cap: $67.2M, Sector: Financial services.
Last analyzed: Mar 18, 2026Analyst Coverage for MJUS: MJUS does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates MJUS against Financial Services peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
MJUS: the 2 scored disciplines are evenly split. Dominant signal: Jim Simons bearish.
How is this calculated? →ETFMG U.S. Alternative Harvest ETF (MJUS) Financial Services Profile
ETFMG U.S. Alternative Harvest ETF (MJUS) is a non-diversified fund targeting U.S. cannabis businesses, allocating at least 80% of its assets to companies deriving over 50% of revenue from the cannabis sector. The fund concentrates at least 25% of its investments in the pharmaceuticals, biotechnology and life sciences industry group.
What Is the Investment Thesis for MJUS?
MJUS presents a targeted investment vehicle for those seeking exposure to the U.S. cannabis market. The fund's strategy of concentrating investments in companies deriving a majority of their revenue from the cannabis business allows for focused participation in the sector's growth. The fund's concentration in pharmaceuticals, biotechnology, and life sciences provides exposure to potential medical advancements and innovations within the cannabis industry. However, the non-diversified nature of the fund increases its risk profile, making it more susceptible to market volatility and regulatory changes specific to the cannabis sector. With a beta of 1.32, MJUS demonstrates higher volatility compared to the broader market, which investors may want to evaluate. The absence of a dividend yield may deter income-focused investors. The fund's performance is closely tied to the evolving regulatory landscape and market acceptance of cannabis in the United States.
Based on FMP financials and quantitative analysis
MJUS Key Highlights
Market Cap of $67.2M indicates a smaller-sized fund within the asset management landscape.
- Beta of 1.32 suggests higher volatility compared to the overall market, potentially offering higher returns but also greater risk.
- The fund invests at least 80% of its net assets in companies deriving at least 50% of their net revenue from the cannabis business in the United States.
- Concentrates at least 25% of its investments in the pharmaceuticals, biotechnology and life sciences industry group, reflecting a focus on the medical applications of cannabis.
- As a non-diversified fund, MJUS is subject to greater risk than a diversified fund because it invests a significant portion of its assets in a smaller number of issuers.
Who Are MJUS's Competitors?
MJUS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| BMVP Invesco Bloomberg MVP Multi-factor ETF | $54.91 | +0.00% | $103M | 49 |
| DRUP GraniteShares Nasdaq Select Disruptors ETF | $68.13 | -1.63% | $49.8M | 44 |
| DVEM WisdomTree Emerging Markets ESG Fund | $26.17 | +7.74% | $67.2M | 44 |
| GGME Invesco Next Gen Media and Gaming ETF | $62.66 | -0.90% | $169M | 44 |
| JANT AllianzIM U.S. Equity Buffer10 Jan ETF | $44.85 | -0.29% | $63.5M | 47 |
| EEA The European Equity Fund, Inc. | $11.15 | -0.59% | $74.7M | 67 |
| HNNA Hennessy Advisors, Inc. | $9.89 | -1.30% | $78.2M | 81 |
| ETHT ProShares - Ultra Ether ETF | $12.57 | +19.94% | $92.2M | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are MJUS's Key Strengths?
Focused exposure to the U.S. cannabis market.
- Concentration in pharmaceuticals, biotechnology, and life sciences.
- Potential for high growth in a rapidly expanding industry.
- Established brand recognition within the ETF market.
What Are MJUS's Weaknesses?
Non-diversified fund, leading to higher risk.
- Subject to regulatory risks and uncertainties in the cannabis industry.
- High beta indicates greater volatility compared to the overall market.
- Absence of dividend yield may deter income-focused investors.
What Could Drive MJUS Stock Higher?
MJUS catalyst: Potential for further legalization of cannabis in additional U.S. states, which could expand the market opportunity for companies held by MJUS.
- Growing acceptance of medical cannabis among healthcare professionals and patients, which could drive demand for cannabis-based pharmaceuticals and therapies.
- Development of innovative cannabis products and therapies, which could drive revenue growth and increase market share for companies held by MJUS.
What Are the Key Risks for MJUS?
Changes in government regulations and policies regarding cannabis, which could negatively impact the industry and the value of companies held by MJUS.
- Negative public perception of cannabis, which could limit consumer demand and hinder the growth of the industry.
- Competition from other cannabis ETFs and investment funds, which could reduce MJUS's market share and AUM.
- The non-diversified nature of the fund increases its risk profile, making it more susceptible to market volatility and regulatory changes specific to the cannabis sector.
What Are the Growth Opportunities for MJUS?
- Expansion of Cannabis Legalization: As more U.S. states legalize cannabis for medical and recreational use, the market opportunity for companies in the cannabis industry will expand. This expansion could lead to increased revenue and profitability for companies held by MJUS. The timeline for further legalization is ongoing, with various states considering legislation each year. The total U.S. cannabis market is projected to reach $40 billion by 2030, offering significant growth potential for MJUS.
- Increased Acceptance of Medical Cannabis: Growing acceptance of medical cannabis among healthcare professionals and patients could drive demand for cannabis-based pharmaceuticals and therapies. This trend could benefit companies in the pharmaceuticals, biotechnology, and life sciences industries that are held by MJUS. The market for medical cannabis is expected to grow to $20 billion by 2028, providing a substantial opportunity for MJUS to capitalize on this trend.
- Development of Innovative Cannabis Products: Companies in the cannabis industry are developing innovative products, such as edibles, beverages, and topicals, that appeal to a broader range of consumers. These new products could drive revenue growth and increase market share for companies held by MJUS. The market for cannabis-infused products is projected to reach $12 billion by 2027, offering a significant growth opportunity for MJUS.
- Mergers and Acquisitions in the Cannabis Industry: The cannabis industry is undergoing consolidation, with larger companies acquiring smaller companies to gain market share and expand their operations. This trend could create opportunities for MJUS to benefit from increased valuations and synergies resulting from these mergers and acquisitions. The value of M&A deals in the cannabis industry is expected to reach $5 billion in 2026, providing potential upside for MJUS.
- Increased Investment in Cannabis Research and Development: Growing investment in cannabis research and development could lead to breakthroughs in understanding the potential health benefits of cannabis and developing new cannabis-based therapies. This research could benefit companies in the pharmaceuticals, biotechnology, and life sciences industries that are held by MJUS. Investment in cannabis R&D is projected to reach $1 billion by 2028, creating opportunities for MJUS to profit from these advancements.
What Are MJUS's Competitive Advantages?
- First-mover advantage in offering a U.S.-focused cannabis ETF.
- Expertise in identifying and investing in companies that are involved in the cannabis business.
- Established brand recognition and distribution network within the ETF market.
What Does MJUS Do?
The ETFMG U.S. Alternative Harvest ETF (MJUS) is designed to provide investors with exposure to the rapidly evolving cannabis industry within the United States. The fund operates under the principle of investing at least 80% of its net assets, plus any borrowings for investment purposes, in the securities of companies that generate at least 50% of their net revenue from what it defines as the “Cannabis Business” in the United States. This includes companies involved in the cultivation, production, distribution, and sale of cannabis and cannabis-related products, as well as those engaged in research and development within the cannabis sector. MJUS also utilizes derivatives that have economic characteristics similar to these securities to further achieve its investment objective. A key aspect of MJUS's investment strategy is its concentration in the pharmaceuticals, biotechnology, and life sciences industry group, where it allocates at least 25% of its investments. This focus reflects the increasing convergence of the cannabis industry with the broader healthcare and scientific sectors, as companies explore the potential medical applications of cannabis and develop innovative cannabis-based products. As a non-diversified fund, MJUS is subject to greater risk than a diversified fund because it invests a significant portion of its assets in a smaller number of issuers. This means that the fund's performance may be more volatile and susceptible to fluctuations in the value of individual holdings.
What Products and Services Does MJUS Offer?
- Invests primarily in securities of companies that derive at least 50% of their net revenue from the cannabis business in the United States.
- Utilizes derivatives that have economic characteristics similar to cannabis-related securities.
- Concentrates at least 25% of its investments in the pharmaceuticals, biotechnology, and life sciences industry group.
- Seeks to provide investment results that correspond generally to the price and yield performance of the U.S. cannabis market.
- Operates as a non-diversified fund, which means it may invest a larger portion of its assets in a smaller number of issuers.
- Offers investors a way to gain exposure to the U.S. cannabis industry through a single investment vehicle.
How Does MJUS Make Money?
- Generates revenue through management fees charged to investors based on the fund's assets under management (AUM).
- Aims to provide capital appreciation by investing in companies that are involved in the cannabis business in the United States.
- Focuses on companies that derive a significant portion of their revenue from the cannabis sector, as well as those in related industries like pharmaceuticals and biotechnology.
What Industry Does MJUS Operate In?
MJUS operates within the asset management industry, specifically targeting the cannabis sector. The cannabis market is experiencing rapid growth and evolving regulatory landscapes. MJUS competes with other ETFs and investment funds that focus on cannabis-related businesses, such as BMVP, DRUP, DVEM, GGME, and JANT. The fund's success depends on its ability to identify and invest in companies that can thrive in this dynamic environment. Market trends include increasing legalization of cannabis in various U.S. states, growing acceptance of cannabis for medical and recreational use, and ongoing research into the potential health benefits of cannabis.
Who Are MJUS's Key Customers?
- Retail investors seeking exposure to the U.S. cannabis market.
- Institutional investors looking to diversify their portfolios with cannabis-related assets.
- Investors who believe in the growth potential of the cannabis industry and its potential medical applications.
ETFMG U.S. Alternative Harvest ETF (MJUS) Valuation Context
Valued at $67.2M, MJUS is classified as a micro-cap stock.
Key Financial Metrics
Return on equity for ETFMG U.S. Alternative Harvest ETF stands at 0.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 0.0%, showing how much profit it generates from its asset base. MJUS trades at a trailing price-to-earnings ratio of 0.00, below the Financial Services sector average of ~18x. Its free cash flow yield is 0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is 0.0%, the inverse of the P/E and a quick read on earnings relative to price.
MJUS Financials
Bull Case vs Bear Case
Bull Case
- MJUS offers diversification across the U.S. cannabis sector, tapping into potential growth as more states legalize. Think of it as similar to investing in the internet in the late 90s – broad exposure to a nascent industry.
- Positive community sentiment suggests growing investor confidence in the long-term prospects of U.S. cannabis. This echoes the early days of renewable energy stocks, where belief fueled initial growth.
- Recent insider activity, if showing buying trends, could signal confidence in the ETF's future performance. It's like executives loading up on their own company's stock before a major product launch.
- Market perception of cannabis is shifting, with increasing acceptance and potential for federal reform. This resembles the changing attitudes toward electric vehicles, paving the way for wider adoption.
Bear Case
- The U.S. cannabis industry faces regulatory hurdles and uncertainty at the federal level, hindering growth. This is akin to the challenges faced by the early cryptocurrency market, where regulatory ambiguity created volatility.
- Community sentiment can be fickle, and a shift towards bearish views could trigger a sell-off. Remember the dot-com bubble burst – initial enthusiasm quickly turned to panic.
- Recent insider activity, if showing selling trends, might indicate concerns about the ETF's future performance. This could mirror executives cashing out before a company restructuring.
- Competition within the U.S. cannabis sector is intensifying, potentially squeezing profit margins for companies held within MJUS. This is similar to the smartphone market, where numerous players battle for market share.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
MJUS Latest News
No recent news available for MJUS.
What Investors Ask About ETFMG U.S. Alternative Harvest ETF (MJUS) — Financial Services
What happened to ETFMG U.S. Alternative Harvest ETF (MJUS) stock?
ETFMG U.S. Alternative Harvest ETF (MJUS) no longer trades on public markets. It was delisted in January 2025. The figures below are historical and are not a current quote.
Can I still buy MJUS shares?
No. MJUS stopped trading on public markets in January 2025, so the shares are not available through a broker. Anything you see quoted for MJUS elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before MJUS stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to ETFMG U.S. Alternative Harvest ETF. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
What does ETFMG U.S. Alternative Harvest ETF do?
The ETFMG U.S. Alternative Harvest ETF (MJUS) is designed to provide investors with exposure to the U.S. cannabis industry. It invests primarily in companies that derive at least 50% of their net revenue from the cannabis business in the United States, as well as in derivatives with similar economic characteristics.
What are the main risks for MJUS?
The main risks for MJUS include regulatory risks, market risks, and concentration risk. Regulatory risks stem from the evolving legal landscape surrounding cannabis in the United States, as changes in federal or state laws could significantly impact the industry. Market risks arise from the volatility of the cannabis market and the potential for fluctuations in the value of cannabis-related securities.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- The cannabis industry is subject to rapid changes in regulations and market conditions.
- The fund's performance is dependent on the success of the companies it invests in.
- Investors should carefully consider the risks associated with investing in a non-diversified fund.